[ad_1]
Pfizer is creating some 300 jobs at its Grange Castle in Co Dublin, Newbridge in Co Kildare and Ringaskiddy in Co Cork manufacturing plants.
The US pharmaceutical company said it is investing around 300 million euros in its Irish operations to support further development of the three sites.
The investment and hiring of the new jobs will be completed in the next two to three years.
Pfizer has operated in Ireland since 1969 and has 4,000 employees at six locations in Cork, Dublin and Kildare.
The new roles comprise a wide range of highly skilled positions including analysts, technicians, engineers, scientists, technologists, quality specialists, data analysts, and chemists.
Pfizer said its latest investment will upgrade and improve its facilities, expand manufacturing and laboratory capacity, and add new technologies to ensure it is ready to support the next wave of medical innovations.
He said part of the investment includes the initial stage of a project to build a development facility at its existing Ringaskiddy site to manufacture pharmaceutical compounds for the company’s clinical trials globally.
“This is a very important development as it expands Pfizer’s role in Ireland from manufacturing already approved drugs to supporting earlier phases of new drug development,” the company said.
Pfizer’s Irish sites manufacture drugs and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, hemophilia, pain, and stroke.
Paul Reid, Country Manager for Pfizer Healthcare Ireland, said the company’s purpose is to discover innovative medicines that change the lives of patients.
These new positions, he said, are key roles within the organization and play an important role in the manufacturing and delivery of drugs to patients around the world.
“We are currently focused on our Covid-19 efforts, including our vaccine development program. Pfizer is also investing significantly in other health care innovations, such as gene therapy and complex biologics targeting some of the most medical conditions. debilitating, “Reid said.
Dr Paul Duffy, Vice President of Pfizer Global Supply, said that pharmaceutical manufacturing here continues to perform very well.
“Pfizer has a broad US and global presence with operations in more than 125 countries around the world and we are very pleased with today’s announcements that will strengthen our Irish operations and bring our total Irish workforce to 4,000,” he said.
“It is also particularly exciting that our Ringaskiddy site has been chosen as the location to manufacture investigational compounds for our clinical trials globally and we look forward to seeing the new facility go live.”
Taoiseach Micheál Martin said that today’s important jobs and investment announcement from Pfizer is one more vote of confidence in the skills and talents of the Irish and provides a very welcome boost to the economy.
“Over the past five decades, there has been a huge expansion of the sector in this country, creating thousands of jobs and solidifying Ireland’s reputation as a world leader in pharmaceutical innovation and manufacturing,” said Martin.
“Pfizer has made a significant contribution to the Irish economy and this latest investment is a testament to the quality and expertise of the workforce here,” he added.
Martin Shanahan, Chief Executive Officer of IDA Ireland, said that today’s investment announcement and the substantial number of additional highly rated positions across his three Irish sites is a huge vote of confidence in Ireland’s investment environment.
Shanahan said it again underlines Ireland’s reputation as a global place of excellence for biopharmaceuticals.
Pfizer hopes to be the first US drug maker to announce successful data from a late-stage Covid-19 vaccine trial.
The company, along with its German partner BioNTech, launched its phase 3 study of 44,000 volunteers of its vaccine in late July.
[ad_2]